Abstract: Pt-xanthene-iodine complex and Pt-xanthene-bromine complex, and use thereof for catalysis of a hydroformylation reaction.

Abstract: Organophosphorus compounds, catalytic systems comprising a metallic element forming a complex with the organophosphorus compounds and methods of hydrocyanation and of hydroformylation employed in the presence of the catalytic systems are described.

Abstract: Described are palladium precatalysts, and methods of making and using them. The palladium precatalysts show improved stability and improved reactivity in comparison to previously-described palladium precatalysts.

Abstract: A process for preparing the S or R enantiomer of a compound of formula A, the process comprising subjecting a compound of formula B to asymmetric hydrogenation in the presence of a chiral transition metal catalyst and a source of hydrogen, wherein X is CH2, oxygen, or sulphur; R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino, or dialkylamino group; and R4 is alkyl or aryl, wherein the transition metal catalyst comprises a chiral ligand having the formula wherein p is from 1 to 6, and Ar means aryl group; wherein the term alkyl means hydrocarbon chains, straight or branched, containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, halogen, alkoxycarbonyl or hydroxycarbonyl groups; the term aryl means an aromatic or heteroaromatic group, optionally substituted by alkyloxy, halogen, or nitro group; and the term halogen means fluorine, chlorine, bromine, or iodine.

Abstract: A composition is capable of curing via condensation reaction. The composition uses a new condensation reaction catalyst. The new condensation reaction catalyst is used to replace conventional tin catalysts. The composition can react to form a gum, gel, rubber, or resin.

Abstract: Described are palladium precatalysts, and methods of making and using them. The palladium precatalysts show improved stability and improved reactivity in comparison to previously-described palladium precatalysts.

Abstract: A phosphate-containing nanoparticle delivery vehicle includes nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.

Abstract: An embodiment of the invention is a novel Cr(V)OCO3? trianionic pincer ligand complex. Another embodiment of the invention is a catalytic method for oxidation of a substrate aerobically in the presence of a source of oxygen, where the novel Cr(V)OCO3? trianionic pincer ligand complex acts as the catalyst. The substrate can be a phosphine, amine, sulfide, alkene, alkane or a second metal complex. Another embodiment of the invention is directed to NCN pincer ligands that can form trianionic pincer ligand complexes.

Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.

Abstract: A phosphate-containing nanoparticle delivery vehicle includes a nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.

Abstract: The present invention relates to processes for the reduction by hydrogenation, using molecular H2, of a C5-C20 substrate containing one or two aldehydes functional groups into the corresponding alcohol or diol, characterized in that said process is carried out in the presence of —at least one catalyst or pre-catalyst in the form of a ruthenium complex having a coordination sphere of the N2P2O2, wherein the coordinating atoms N2 are provided by a first bidentate ligand, the coordinating atoms P2 are provided by a second bidentate ligand and the coordinating atoms O2 are provided by two non-linear carboxylate ligands; and —optionally of an acidic additive.

Abstract: The present invention relates to a method of obtaining metal nanoparticles functionalized with fluorescent organic molecules by means of the treatment of one or more metal salts with a reducing agent in the presence of a fluorescent organic molecule. The invention also relates to the metal nanoparticles obtainable by said method and to their use for detecting molecules and analytes.

Abstract: A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable of undergoing hydrosilylation reaction. The composition capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin. Ingredient (A) contains a metal-ligand complex that can be prepared by a method including reacting a metal precursor and a ligand.

Abstract: A phosphine-based catalyst composition suitable for the telomerization of butadiene to produce 1-octene includes palladium and one of a class of novel phosphine ligands characterized by two potentially functionalized phenyl rings and cyclized 5- or 6-member alkoxy groups that, together, bridge the two potentially functionalized phenyl rings. In these groups the alkoxy moiety of each is located ortho to at least one functionalizing moiety, if any, on the phenyl rings. The catalysts including this class of phosphine ligands may exhibit higher catalytic activity and selectivity, and may be used at lower temperatures, than many other phosphine ligand catalysts, reducing costs. Palladium precipitation may also be reduced.

Abstract: Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific antigen (PSA), prostate specific membrane antigen (PSMA) or human glandular kallikrein (hK2). Various further embodiments relate more specifically to PSMA-specific peptide prodrugs that become activated to yield therapeutic drugs. Further aspects of various embodiments of the present invention also relate to methods and compositions for treating or preventing cancers and methods and compositions for detecting and/or imaging cancers.

Abstract: This disclosure relates to graphene derivatives, as well as related devices including graphene derivatives and methods of using graphene derivatives.

Abstract: The molecular structures of metal-salen complexes which exerts pharmacological effects are clarified and the metal-salen complexes having such molecular structures and their derivatives are provided. A metal-salen complex compound is characterized in that a metal atom part in each of multiple molecules of the metal-salen complex or its derivative is multimerized via water.

Abstract: Described are palladium precatalysts, and methods of making and using them. The palladium precatalysts show improved stability and improved reactivity in comparison to previously-described palladium precatalysts.

Abstract: The present invention provides rotenone analogs and methods of making and using them. Labeled with single photon and positron emitting isotopes, the rotenone analogs of the present invention are useful in, for example, clinical imaging applications as tracers to measure cardiac blood flow and detect regions of ischemia.

Abstract: Organophosphorus compounds are described that belong to the phosphinite-phosphite family. Catalytic systems comprising a metallic element forming a complex with said phosphinite-phosphite compounds and methods of hydrocyanation employed in the presence of said catalytic systems are also described.

Abstract: The present invention discloses a physical nano-complex for preventing and treating cancer and a method for manufacturing the same. The composition contains EGCG and nanogold, wherein the ratio of the EGCG to the nanogold is in a range from 23:0.5˜23:10 (ppm/ppm). The present invention further discloses a method for manufacturing the composition, wherein the method is to mix the EGCG and the nanogold sufficiently by an ultrasonication process, which makes the EGCG and the nanogold combine to each other well.

Abstract: A phosphine-based catalyst composition suitable for the telomerization of butadiene to produce 1-octene includes palladium and one of a class of novel phosphine ligands characterized by two potentially functionalized phenyl rings and a third phenyl group having an alkoxy functionality on one of the ortho-positions, which is part of a 5- or 6-membered ring between this ortho position and the adjacent meta position, this ring not being part of a second aryl group. The catalysts including this class of phosphine ligands may exhibit higher catalytic activity and selectivity, and may be used at lower temperatures, than many other phosphine ligand catalysts, reducing costs. Palladium precipitation may also be reduced.

Abstract: The present invention relates to organophosphorus compounds belonging to the phosphinite-phosphite family, catalytic systems comprising a metallic element forming a complex with said phosphinite-phosphite compounds and methods of hydrocyanation employed in the presence of said catalytic systems.

Abstract: A phosphate-containing nanoparticle delivery vehicle includes a nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.

Abstract: A pharmaceutical composition is provided that is useful for reducing sodium in the bloodstream of animals. In some embodiments, the pharmaceutical composition comprises a high-ion-affinity part and a substrate part. Additionally, methods of using the pharmaceutical composition and methods of treating diseases with the pharmaceutical composition are disclosed.

Abstract: The present invention relates to a use of a cyclic imidate as a ligand for catalysis in which the ligand contains sub-structure (Y) as a minimal structural motive, wherein the carbon atoms and the nitrogen atom can be optionally substituted by a chemical substituent.

Abstract: The present technology relates gold sub-nanoclusters comprising a gold core and one or more thiolates bound to the gold core, wherein the gold core consists essentially of 23 gold atoms. Methods of preparing and using such sub-nanoclusters are also provided.

Abstract: Organophosphorus compounds, catalytic systems comprising a metallic element forming a complex with the organophosphorus compounds and methods of hydrocyanation and of hydroformylation employed in the presence of the catalytic systems are described.

Abstract: Discussed herein are a charge control agent and toner comprising said charge control agent. Said toner of the invention is comprised of a resin, a colorant, and the charge control agent, wherein, said charge control agent is comprised of a specific type of metal complexes. In the invention, the charge control agent has excellent charge control properties and the characteristics of uniform crystalline size, high charge speed, high thermo stability, low moisture absorption, and good compatibility with resin. The toner of the invention has excellent electrical characteristics and produces stable image of high quality under a wide range of environmental conditions without dusting and fogging.

Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.

Abstract: A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof.

Abstract: A process for preparing the S or R enantiomer of a compound of formula A, the process comprising subjecting a compound of formula B to asymmetric hydrogenation in the presence of a chiral transition metal catalyst and a source of hydrogen, wherein X is CH2, oxygen, or sulphur; R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino, or dialkylamino group; and R4 is alkyl or aryl, wherein the transition metal catalyst comprises a chiral ligand having the formula wherein p is from 1 to 6, and Ar means aryl group; wherein the term alkyl means hydrocarbon chains, straight or branched, containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, halogen, alkoxycarbonyl or hydroxycarbonyl groups; the term aryl means an aromatic or heteroaromatic group, optionally substituted by alkyloxy, halogen, or nitro group; and the term halogen means fluorine, chlorine, bromine, or iodine.

Abstract: A phosphate-containing nanoparticle delivery vehicle includes a nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.

Abstract: The invention relates to a process for producing a complex for use in olefin polymerization and oligomerization of the general formula (III): wherein Mt is a group 3 to 12 element in a +2 to +6 oxidation state with between 1 to 4 additional ligands (anionic and/or neutral) coordinated, wherein R1 and R2 are hydrogen, halogen, alkoxy, or a hydrocarbon group containing between 1 to 12 carbon atoms; E is a group 16 element, preferably O; Z is a direct bond between carbon atoms of the adjacent aromatic rings or a —CR3R4— or —SiR3R4— bridge between those carbon atoms, where R3 and R4 are hydrogen or a hydrocarbon groups with 1 to 10 carbons, R5, R6, R7 and R8 are hydrogen, halogen, alkoxy, or a hydrocarbon group containing between 1 to 10 carbon atoms and J1 and J2 are —NR9R10 or —PR9R10, where R9 is H or SiMe3 group and R10 is selected from a group consisting of alkyl, aryl, substituted aryl, heteroalkyl, and heteroaryl containing between 1 to 30 non-hydrogen atoms through a route involving novel precursors s

Abstract: This invention relates to certain complexes of ascorbic acid and its derivatives with certain natural antioxidant and anti-inflammatory ketones for topical or oral application; said complexes having general chemical formula (I), its isomers, and salts thereof, including their optically active or racemic forms.

Abstract: One aspect of the invention relates to a metal-catalyzed conversion of aryl halides and sulfonates to the corresponding aryl fluorides. Another aspect of the invention relates to a metal-catalyzed conversion of heteroaryl halides and sulfonates to the corresponding heteroaryl fluorides. Another aspect of the invention relates to a metal-catalyzed conversion of vinyl halides and sulfonates to the corresponding vinyl fluorides. In certain embodiments, simple fluoride sources, such as AgF and CsF, are used. In certain embodiments, the transformations tolerate a wide range of functional groups, allowing for introduction of fluorine atoms into highly functionalized organic molecules.

Abstract: A pigment having at least two layers according to the following structure (I), where C is an internal pigment core of formula [Mx(O)y(OH)z]; where MX=TiIV, ZnII, ZrIV, SnIV, FeII, FeIII, SnII, CrVI, or MnII; x=2, 3 or 4; and (y/2+z)=x; A is a plant polyphenol having an active-redox, radical scavanger behaviour and at least two chelating moieties and B is an outer hydrophobic layer consisting in an anionic surfactant, and where Ma and Mb denotes, each independently, Mq+=Ca2+, Zn2+, Ti4+, Si4+, Al3+, Sn4+, Mg2+, or Sr2+; and a=0 or 1; b=1; q=2, 3 or 4.

Abstract: The subject invention concerns methods and materials for cancer screening using platinum complexes to detect a STAT protein biomarker. Platinum (IV) complexes interacting with STATs directly correlate with the STAT expression. In one embodiment, fluorescently-labeled and/or antibody-linked platinum (IV) complexes can be used to assess the STAT expression and define malignant potential. Other methods such as imaging (MRI, e.g.) can also be used to assess platinum-STAT interactions. The STAT protein can be, for example, STAT3.

Abstract: A process for making diphosphine-ruthenium-diamine complexes by reacting a phosphine compound with an arene ruthenium compound in a first solvent to produce an intermediate mixture comprising a diphosphine-ruthenium compound, the first solvent consisting essentially of a mixture of an aprotic solvent and a protic solvent; then removing the first solvent from the intermediate mixture to produce an intermediate solid comprising the diphosphine-ruthenium compound; and then contacting the intermediate solid comprising the diphosphine-ruthenium compound with a diamine and a second solvent to produce the diphosphine-ruthenium-diamine complex, the second solvent consisting essentially of an aprotic solvent selected from the group consisting of ethers and hydrocarbon solvents.

Abstract: Fermentation of a nutrient medium with a eubacterium Streptomyces sp. yields a novel antibacterial compound of structure (I).

Abstract: The invention relates to a labeled transition metal complex comprising a transition metal atom, a reactive moiety for allowing a chemical or biological entity to become attached to the transition metal atom, an inert tridentate moiety as a stabilizing bridge, and a marker. The invention also relates to a labeled chemical or biological entity comprising a chemical or biological entity which is attached to said labeled transition metal complex, to the use of said complex for creating a defined shift in the molecular mass of said entity in order to facilitate mass spectrometric analysis of said entity, to methods for rendering chemical or biological entities distinguishable by mass spectrometry as well as to methods for mass spectrometric analysis of the chemical or biological entities.

Abstract: Rhodamine, thio-rhodamine, acridine, and carbopyronin compounds of the formula wherein M is either (1) a metal ion having a positive charge of +y wherein y is an integer which is at least 2, said metal ion being capable of forming a compound with at least two chromogen moieties, or (2) a metal-containing moiety capable of forming a compound with at least two chromogen moieties, z is an integer representing the number of chromogen moieties associated with the metal and is at least 2, R1, R2, R3, R4, R5, R6, R7, a, b, c, d, Y, and z are as defined herein, Q? is a COO? group or a SO3? group, A is an organic anion, and CA is either a hydrogen atom or a cation associated with all but one of the Q? groups.

Abstract: A fluorescent compound exhibiting a high affinity to calcium-binding proteins (CaBP) is provided. The compound, containing ruthenium, enables to detect, identify, and isolate CaBPs involved in cellular signaling and regulation. The compound is employed for diagnosing a disorder associated with CaBPs defects.

Abstract: The invention relates to a process for producing a complex for use in olefin polymerization and oligomerization of the general formula (III): wherein Mt is a group 3 to 12 element in a +2 to +6 oxidation state with between 1 to 4 additional ligands (anionic and/or neutral) coordinated, wherein R1 and R2 are hydrogen, halogen, alkoxy, or a hydrocarbon group containing between 1 to 12 carbon atoms; E is a group 16 element, preferably O; Z is a direct bond between carbon atoms of the adjacent aromatic rings or a —CR3R4— or —SiR3R4— bridge between those carbon atoms, where R3 and R4 are hydrogen or a hydrocarbon groups with 1 to 10 carbons, R5, R6, R7 and R8 are hydrogen, halogen, alkoxy, or a hydrocarbon group containing between 1 to 10 carbon atoms and J1 and J2 are —NR9R10 or —PR9R10, where R9 is H or SiMe3 group and R10 is selected from a group consisting of alkyl, aryl, substituted aryl, heteroalkyl, and heteroaryl containing between 1 to 30 non-hydrogen atoms through a route involving novel precursors s

Abstract: The present invention concerns a metallocene-based phosphine ligand for use in enantioselective catalysis, the ligand having the Formula (I): Wherein M is a metal; Z is P or As; L is a suitable linker; R1 is selected from alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkoxy, cycloalkylamino carbocyclic aryl, substituted and unsubstituted carbocyclic aryloxy, heteroaryl, heteroaryloxy, carbocyclic arylamino and heteroarylamino; X* is selected from (II): Wherein R, R2 and R3 are independently selected from optionally substituted branched- and straight-chain alkyl, cycloalkyl, heterocycloalkyl, carbocyclic aryl, and heteroaryl.

Abstract: An organic light emitting device is provided. The device has an anode, a cathode and an organic layer disposed between the anode and the cathode. The organic layer comprises a compound further comprising one or more carbene ligands coordinated to a metal center.

Abstract: An OLED device comprises a cathode, an anode, and has therebetween a light emitting layer comprising a phosphorescent emitter represented by Formula (I): LnM ??(I) wherein each L is a cyclometallated ligand with at least one containing a coumarin group, M is Ir or Pt, and n is 3 when M is Ir and 2 when M is Pt. The invention also comprised the compound of formula (I).

Abstract: Compounds of the formula wherein M is either (1) a metal ion having a positive charge of +p wherein p is an integer which is at least 2, said metal ion being capable of forming a compound with at least two chromogen moieties, or (2) a metal-containing moiety capable of forming a compound with at least two chromogen moieties, z is an integer representing the number of chromogen moieties associated with the metal and is at least 2, and R1, R2, R3, R4, R5, R6, R7, a, b, c, d, Y, Q?, A, and CA are as defined herein.

Abstract: A metallocene compound of formula (I): wherein M is zirconium, titanium and hafnium; X is a hydrogen atom, a halogen atom or a hydrocarbon radical; R1 is a linear C1-C20-alkyl radical; R2 is a hydrogen atom or hydrocarbon R3, R4, R5, R6, R7, and R8, are hydrogen atoms or hydrocarbon radicals, A is a sulphur (S) atom or an oxygen (O) atom; Q is a radical of formula (II), (III) or (IV) being bonded to the indenyl at the position indicated by the symbol *; (II), (III), (IV) wherein T1 is a sulphur atom, an oxygen (O) atom or a NR; R9, R10 and R11 are hydrogen atoms or hydrocarbon radicals; T2, T3, T4, T5, and T6 are carbon atoms (C) or nitrogen atoms (N); m1, m2, m3, m4 and m5 are 0 or 1; R12, R13, R14, R15 and R16 are hydrogen atoms or hydrocarbon radicals with the provisos that at least one of R12, R13, R14, R15 and R16 is different from hydrogen atoms, and that no more than two of T2, T3, T4, T5 and T6 are nitrogen atoms.

Abstract: A process for producing an organotitanium compound capable of regioselectively converting a substituted acetylene compound into polysubstituted benzene or polysubstituted pyridine. The process comprises reacting an acetylene compound represented by the formula (1) [where R1 and R2 denote a C1-20 alkyl group or the like] in the presence of a prescribed titanium compound and a Grignard reagent with a compound represented by the formula (4) [where R3 and R4 denote a hydrogen atom or the like] and further reacting with a compound represented by the formula (5) [where R5 denotes a hydrogen atom or the like, Z denotes CR? (where R? denotes a hydrogen atom or the like), nitrogen atom, X6 denotes a halogen atom or the like, and m is 0 or 1] thereby giving the titanium compound represented by the formula (6) and/or (7). [where R1˜R5, Z, X6, and m are defined as above; and Xp and Xq denote any of X1˜X4].